EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC 4.0

A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata

Mercedes E Gonzalez, John Browning, Stacy Smith, Anna Plotka, Jing Daisy Zhu, Shyam Parvatini, Yeamin Huh, Robert Wolk

Pediatric Dermatology · 2025-07 · 42 (4) · 742-746

DOI: 10.1111/pde.15895 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Pediatric Dermatology, online erschienen am 09.02.2025. Verfasst von Mercedes E Gonzalez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Skin Research, Coral Gables, Florida, USA. Hauptthemen laut MEDLINE: Alopecia Areata, Protein Kinase Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alopecia areata (AA) is an autoimmune disease characterized by hair loss that can negatively impact quality of life. AA has a significant pediatric prevalence; however, no systemic treatments are approved for AA in patients aged < 12 years. Ritlecitinib, a JAK3/TEC family kinase inhibitor, is approved to treat adults and adolescents with severe AA aged ≥ 12 years. This study evaluated ritlecitinib pharmacokinetic (PK) parameters and safety in pediatric patients with AA aged 6 to < 12 years.

Methods

In this single‐group, uncontrolled, open‐label study, participants received ritlecitinib 20 mg once daily for 7 days. PK parameters of ritlecitinib on Day 7 were measured and summarized descriptively. Safety outcomes, including incidence of adverse events (AEs), were evaluated.

Results

Fifteen participants were enrolled and 14 (93.3%) completed the study. The median time to maximum concentration (T max ) for plasma concentrations of ritlecitinib on Day 7 was ~0.5 h. The mean half‐life of ritlecitinib was ~1.19 h. Geometric means (% coefficient of variation) for area under the curve from 0 to 24 h (AUC 24 ) and maximum concentration (C max ) were 437.5 ng·h/mL (30%) and 208.7 ng/mL (38%), respectively. Four AEs were experienced by 3 participants, with 1 AE of urticaria resulting in permanent discontinuation. No severe AEs, serious AEs, or clinically meaningful laboratory abnormalities were reported.

Conclusions

Ritlecitinib PK parameters in pediatric patients were successfully characterized in the present study. Ritlecitinib 20 mg once daily was generally well tolerated in pediatric patients with AA. Trial Registration NCT05650333

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataProtein Kinase InhibitorsChildFemaleHumansMale

Stichwörter der Autor:innen

alopecia areatachildrenclinical trialpediatricspharmacokinetics

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Pediatric Skin Research, Coral Gables, Florida, USA.
  • University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
  • California Dermatology and Clinical Research Institute, Encinitas, California, USA.
  • Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Pfizer Healthcare India Pvt Ltd, Chennai, India.
  • Pfizer Inc, Groton, Connecticut, USA.

Förderung

  • Pfizer

Zitieren

APA

Gonzalez, M. E., Browning, J., Smith, S., Plotka, A., Zhu, J. D., Parvatini, S., Huh, Y., & Wolk, R. (2025). A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata. Pediatric Dermatology, 42(4), 742-746. https://doi.org/10.1111/pde.15895

Vancouver

Gonzalez ME, Browning J, Smith S, Plotka A, Zhu JD, Parvatini S, et al. A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata. Pediatric Dermatology. 2025;42(4):742-746. doi:10.1111/pde.15895

BibTeX
@article{Gonzalez2025,
  author = {Gonzalez, Mercedes E and Browning, John and Smith, Stacy and Plotka, Anna and Zhu, Jing Daisy and Parvatini, Shyam and Huh, Yeamin and Wolk, Robert},
  title = {A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata},
  journal = {Pediatric Dermatology},
  year = {2025},
  volume = {42},
  number = {4},
  pages = {742--746},
  doi = {10.1111/pde.15895}
}
Kostenlos starten →